EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

EpEX, the soluble extracellular domain of EpCAM, resists cetuximab treatment of EGFR-high head and neck squamous cell carcinoma

Published:2023-07 Issue: Volume:142 Page:106433
ISSN:1368-8375
Container-title:Oral Oncology
language:en
Short-container-title:Oral Oncology

Author:

Umemori Koki,Ono Kisho^ORCID,Eguchi Takanori,Kawai Hotaka,Nakamura Tomoya,Ogawa Tatsuo,Yoshida Kunihiro,Kanemoto Hideka,Sato Kohei,Obata Kyoichi,Ryumon Shoji,Yutori Hirokazu,Katase Naoki,Okui Tatsuo,Nagatsuka Hitoshi,Ibaragi Soichiro

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Oral Surgery

Reference49 articles.

1. Carcinogenic epithelial-mesenchymal transition initiated by oral cancer exosomes is inhibited by anti-EGFR antibody cetuximab;Fujiwara;Oral Oncol,2018

2. Anti-EGFR antibody cetuximab is secreted by oral squamous cell carcinoma and alters EGF-driven mesenchymal transition;Fujiwara;Biochem Biophys Res Commun,2018

3. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma;Shimizu;Int J Oncol,2019

4. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab;Li;Cancer Cell,2005

5. Platinum-based chemotherapy plus cetuximab in head and neck cancer;Vermorken;N Engl J Med,2008

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of the Function and Expression of EpCAM;Biomedicines;2024-05-20

2. Cetuximab chemotherapy resistance: Insight into the homeostatic evolution of head and neck cancer (Review);Oncology Reports;2024-04-19

3. Novel mechanism of cisplatin resistance in head and neck squamous cell carcinoma involving extracellular vesicles and a copper transporter system;Head & Neck;2024-01-02

4. Rab11 suppresses head and neck carcinoma by regulating EGFR and EpCAM exosome secretion;Journal of Oral Biosciences;2023-12

5. EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer;Oral Oncology;2023-08